Mostrar el registro sencillo del ítem
dc.contributor.author
Arrua, Eva Carolina
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Hartwig, Olga
dc.contributor.author
Loretz, Brigitta
dc.contributor.author
Murgia, Xabier
dc.contributor.author
Ho, Duy Khiet
dc.contributor.author
Bastiat, Guillaume
dc.contributor.author
Lehr, Claus Michael
dc.contributor.author
Salomon, Claudio Javier
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2024-03-13T11:52:16Z
dc.date.issued
2023-06
dc.identifier.citation
Arrua, Eva Carolina; Hartwig, Olga; Loretz, Brigitta; Murgia, Xabier; Ho, Duy Khiet; et al.; Formulation of benznidazole-lipid nanocapsules: Drug release, permeability, biocompatibility, and stability studies; Elsevier B.V.; International Journal of Pharmaceutics; 642; 6-2023; 1-11
dc.identifier.issn
0378-5173
dc.identifier.uri
http://hdl.handle.net/11336/230322
dc.description.abstract
Benznidazole, a poorly soluble in water drug, is the first-line medication for the treatment of Chagas disease, but long treatment periods at high dosages cause several adverse effects with insufficient activity in the chronic phase. According to these facts, there is a serious need for novel benznidazole formulations for improving the chemotherapy of Chagas disease. Thus, this work aimed to incorporate benznidazole into lipid nanocapsules for improving its solubility, dissolution rate in different media, and permeability. Lipid nanocapsules were prepared by the phase inversion technique and were fully characterized. Three formulations were obtained with a diameter of 30, 50, and 100 nm and monomodal size distribution with a low polydispersity index and almost neutral zeta potential. Drug encapsulation efficiency was between 83 and 92% and the drug loading was between 0.66 and 1.04%. Loaded formulations were stable under storage for one year at 4 °C. Lipid nanocapsules were found to protect benznidazole in simulated gastric fluid and provide a sustained release platform for the drug in a simulated intestinal fluid containing pancreatic enzymes. The small size and the almost neutral surface charge of these lipid nanocarriers improved their penetration through mucus and such formulations showed a reduced chemical interaction with gastric mucin glycoproteins. LNCs. The incorporation of benznidazole in lipid nanocapsules improved the drug permeability across intestinal epithelium by 10-fold compared with the non-encapsulated drug while the exposure of the cell monolayers to these nanoformulations did not affect the integrity of the epithelium.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier B.V.
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
NEGLECTED TROPICAL DISEASES
dc.subject
CHAGAS DISEASE
dc.subject
TRYPANOSOMA CRUZI
dc.subject
BENZNIDAZOLE
dc.subject
LIPID NANOCAPSULES
dc.subject.classification
Nano-procesamiento
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Nanotecnología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
INGENIERÍAS Y TECNOLOGÍAS
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Formulation of benznidazole-lipid nanocapsules: Drug release, permeability, biocompatibility, and stability studies
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-03-12T11:00:42Z
dc.journal.volume
642
dc.journal.pagination
1-11
dc.journal.pais
Países Bajos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Arrua, Eva Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
dc.description.fil
Fil: Hartwig, Olga. Helmholtz Institute for Pharmaceutical Research Saarland; Alemania
dc.description.fil
Fil: Loretz, Brigitta. Helmholtz Institute for Pharmaceutical Research Saarland; Alemania
dc.description.fil
Fil: Murgia, Xabier. Universitat Saarland; Alemania
dc.description.fil
Fil: Ho, Duy Khiet. Helmholtz Institute for Pharmaceutical Research Saarland; Alemania
dc.description.fil
Fil: Bastiat, Guillaume. No especifíca;
dc.description.fil
Fil: Lehr, Claus Michael. Universitat Saarland; Alemania
dc.description.fil
Fil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina
dc.journal.title
International Journal of Pharmaceutics
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0378517323005409
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.ijpharm.2023.123120
Archivos asociados